Literature DB >> 33873266

Prognostic utility of dynapenia in patients with cardiovascular disease.

Shota Uchida1, Kentaro Kamiya2, Nobuaki Hamazaki3, Kohei Nozaki3, Takafumi Ichikawa3, Takeshi Nakamura1, Masashi Yamashita1, Emi Maekawa4, Jennifer L Reed5, Minako Yamaoka-Tojo6, Atsuhiko Matsunaga6, Junya Ako4.   

Abstract

BACKGROUND: Dynapenia, defined as age-associated loss of skeletal muscle strength, is associated with increased mortality rate, poor activities of daily living, and reduced quality of life. Therefore, dynapenia appears to be a better independent predictor of mortality than sarcopenia in the elderly. However, the prognostic utility of dynapenia in patients with cardiovascular disease (CVD) is not clear. This study was performed to examine the prognostic utility of dynapenia defined by the criteria of Manini et al. in patients with CVD.
METHODS: The findings of 4192 consecutive patients ≥30 years old (median [interquartile range (IQR)] age 69 [60-76] years, 2874 males) with CVD were reviewed. Grip strength and quadriceps isometric strength (QIS) were measured just before hospital discharge, and low grip strength (<26 kg in males and <18 kg in females), low QIS (<45.0% body mass [BM] and <35.0% BM in males and females, respectively) were considered to indicate dynapenia. The endpoint was all-cause mortality.
RESULTS: A total of 507 deaths occurred during follow-up (median 2.0 years, IQR 0.8-4.4 years). The overall prevalence of dynapenia was 33.6% and increased with age (p for trend < 0.01). Females showed a significantly higher prevalence rate of dynapenia than males (43.3% vs. 29.2%, respectively; p < 0.01). Patients with dynapenia showed higher all-cause mortality rate than non-dynapenia patients (adjusted hazard ratio: 1.84; 95% confidence interval: 1.51-2.23; p < 0.01).
CONCLUSIONS: Dynapenia has a high prevalence among patients with CVD and is associated with increased mortality rate.
Copyright © 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Muscle; Physical performance; Rehabilitation; Risk factors

Year:  2020        PMID: 33873266     DOI: 10.1016/j.clnu.2020.09.050

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  3 in total

1.  Association between SGLT2 Inhibitors and Cardiac Rehabilitation Outcomes in Patients with Cardiovascular Disease and Type 2 Diabetes Mellitus.

Authors:  Ayuko Kashima; Kentaro Kamiya; Nobuaki Hamazaki; Kensuke Ueno; Kohei Nozaki; Takafumi Ichikawa; Masashi Yamashita; Shota Uchida; Takumi Noda; Kazuki Hotta; Emi Maekawa; Minako Yamaoka-Tojo; Atsuhiko Matsunaga; Junya Ako
Journal:  J Clin Med       Date:  2022-10-09       Impact factor: 4.964

2.  Associations between dynapenia, cardiovascular hospitalizations, and all-cause mortality among patients on haemodialysis.

Authors:  Shun Yoshikoshi; Shohei Yamamoto; Yuta Suzuki; Keigo Imamura; Manae Harada; Shiwori Osada; Kentaro Kamiya; Atsuhiko Matsunaga
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-08-02       Impact factor: 12.063

3.  The effect of higher versus lower protein delivery in critically ill patients: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Zheng-Yii Lee; Cindy Sing Ling Yap; M Shahnaz Hasan; Julia Patrick Engkasan; Mohd Yusof Barakatun-Nisak; Andrew G Day; Jayshil J Patel; Daren K Heyland
Journal:  Crit Care       Date:  2021-07-23       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.